Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02430532 · ClinicalTrials.gov registry record · Phase 3
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
A Phase 3 study, sponsored by Biogen.
- Terminated
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT02430532 is a Phase 3 study that was terminated before completion, run by Biogen. The registered enrollment target is 58 participants.
The verdict
NCT02430532, a Phase 3 study, was terminated before completion, sponsored by Biogen.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.
Interventions
- OTHER Placebo
- DRUG dimethyl fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02430532
The ClinicalTrials.gov registry entry for NCT02430532 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02430532 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02430532 about?
NCT02430532 is a clinical study titled "BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis". The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to ...
What is the current status of trial NCT02430532?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2015-05. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02430532?
The interventions under investigation include: Placebo (OTHER), dimethyl fumarate (DRUG).
Who is sponsoring clinical trial NCT02430532?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.